Clinical Trials Logo

Clinical Trial Summary

The study is an bridging study, observer-blind, randomized, controlled prospective intervention study. The primary objective is evaluate the safety of BCG Vaccine Vial (Bio Farma).


Clinical Trial Description

This trial is bridging study, observer blinded, comparative, randomized study. Approximately 220 subjects will be recruited, 110 subjects are the investigational arm and 110 subjects are the active comparator arm. The objective of the study is to evaluate the safety of BCG Vaccine Vial (Bio Farma), and assess the the local and systemic reactions within 90 days after vaccination in each group, and assess the tuberculin conversion in each group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05124340
Study type Interventional
Source PT Bio Farma
Contact Rini Mulia Sari, MD
Phone +622033755
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date December 15, 2021
Completion date August 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04899765 - Measles and BCG Vaccines for Mother and Child Phase 4
Not yet recruiting NCT03548233 - BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects . N/A
Not yet recruiting NCT03947138 - A Study of GC3107(BCG Vaccine) in Healthy Infants Phase 3
Recruiting NCT04648800 - Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland Phase 3
Recruiting NCT04673227 - Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)